卢拉西引起的皮疹在老中国患者中出现双极性障碍:基于病例的综述
Wenjuan Yang1,2,3, Danhong Hu4, Bei Zheng1,2
1Department of Pharmacy, Tongde Hospital of ZheJiang Province, Hangzhou, Zhejiang, People's Republic of China.
BMC psychiatry
|July 8, 2024
概括
皮疹是抗精神病药物的已知副作用之一. 这项研究报告了一例罕见的双相情感障碍患者的卢拉西诱导皮疹病例,强调了在剂量调整期间需要保持警.
科学领域:
- 精神病学是一个精神病学.
- 皮肤病学 皮肤病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 药物不良反应,包括皮疹,在抗精神病药物中很常见.
- 很少有人报道了路拉西诱导的皮肤反应.
- 这项研究详细介绍了与卢拉西治疗相关的皮疹病例.
研究的目的:
- 报告一个由卢拉西引起的皮疹病例.
- 审查关于抗精神病药物相关皮疹的现有文献.
- 提高对抗精神病药物潜在皮肤不良事件的认识.
主要方法:
- 一个63岁的双相情感障碍男性在卢拉西治疗中的病例报告.
- 使用多个数据库 (PubMed,Embase,Cochrane,CNKI,Wanfang) 对抗精神病药物相关皮疹的文献综述.
- 包括139篇文章,详细介绍了172名患有抗精神病药物引起的皮疹的患者.
主要成果:
- 患者在增加卢拉西剂量从每天40毫克增加到每天60毫克后出现了一般性皮疹.
- 停止使用卢拉西导致皮疹在两周内完全消失.
- 文献审查证实,抗精神病药物可以引起皮肤不良事件.
结论:
- 卢拉西可以引起皮疹,这是一个罕见但显著的不良药物反应.
- 应考虑抗精神病药物诱导的皮疹,特别是在初始使用或剂量升级期间.
- 医疗保健提供者应监测患者的皮肤反应时,处方抗精神病药物.
相关概念视频
Mania and Antimanic Drugs: Overview
163
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
163
Antidepressant Drugs: MAOIs and Other Agents
215
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
215
Drugs for Treatment of Diarrhea-Predominant IBS
156
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
156


